Paul Manning

Paul Manning

Voorzitter bij CANDEL THERAPEUTICS, INC.

Vermogen: 266 M $ op 30-04-2024

68 jaar
Health Technology
Technology Services
Finance

Profiel

Paul B.
Manning
was the founder of PBM Products LLC (founded in 1997) and PBM Capital Group LLC (founded in 2010), where he holds the titles of President & Chief Executive Officer and Chairman and CEO, respectively.
Mr. Manning is also the founder of Able Laboratories, Inc. Mr. Manning's current job(s) include President & Chief Executive Officer at PBM Capital Investments LLC, Chairman at Candel Therapeutics, Inc. (since 2021), Chairman at Xalud Therapeutics, Inc., Chairman at Verrica Pharmaceuticals, Inc. (since 2017), Director at PatientsLikeMe LLC (since 2022), Director at The Foundation Fighting Blindness, Inc., Director at Foundation Fighting Blindness Clinical Research Institute, Director at PBM Pharmaceuticals, Inc., Independent Director at ArcherDX LLC (since 2015), Director at Tolerion, Inc., Director at UVA Health Foundation, Independent Director at Liquidia Corp.
(since 2020), and Member at University of Virginia Community Credit Union.
Mr. Manning's former job(s) include Chairman at Dova Pharmaceuticals, Inc. (2017-2019), Director at QIAGEN Beverly LLC, Director at Gen9, Inc., Director at Advanz Pharma Corp.
Ltd.
(2014-2015), Independent Director at Novartis Gene Therapies, Inc. (2014-2018), Independent Director at Taysha Gene Therapies, Inc. (2020-2023), Director at RareGen LLC (2018-2020), and Executive Vice President & General Manager at Perrigo Co. (2010-2014).
Mr. Manning's education history includes an undergraduate degree from the University of Massachusetts.
Mr. Manning is also the founder of Able Laboratories, Inc...

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
31-03-2024 15 589 481 ( 36.75% ) 104 M $ 30-04-2024
26-04-2024 6 245 114 ( 8.21% ) 77 M $ 30-04-2024
31-03-2024 23 417 778 ( 12.52% ) 54 M $ 30-04-2024
15-05-2024 2 877 158 ( 9.80% ) 20 M $ 30-04-2024
08-04-2024 3 205 128 ( 5.33% ) 10 M $ 30-04-2024
29-04-2024 130 434 ( 12.51% ) 944 342 $ 30-04-2024

Actieve functies van Paul Manning

BedrijvenFunctieBegin
VERRICA PHARMACEUTICALS INC. Voorzitter 01-12-2017
LIQUIDIA CORPORATION Directeur/Bestuurslid 18-11-2020
CANDEL THERAPEUTICS, INC. Voorzitter 15-07-2021
Corporate Officer/Principal -
Directeur/Bestuurslid 19-01-2022
Voorzitter -
Directeur/Bestuurslid -
Directeur/Bestuurslid 01-01-2015
Directeur/Bestuurslid -
░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ -
Alle actieve functies van Paul Manning

Eerdere bekende functies van Paul Manning

BedrijvenFunctieEinde
░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Ervaring van Paul Manning in detail bekijken

Opleiding van Paul Manning

University of Massachusetts Undergraduate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Paul Manning in detail bekijken

Connecties

100 +

Eerstegraads connecties

26

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven4
CANDEL THERAPEUTICS, INC.

Health Technology

VERRICA PHARMACEUTICALS INC.

Health Technology

TAYSHA GENE THERAPIES, INC.

Health Technology

LIQUIDIA CORPORATION

Health Technology

Bedrijven in privébezit21
Able Laboratories, Inc.

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Consumer Non-Durables

Commercial Services

Finance

Beta-Pro LLC

Finance

Finance

Health Technology

Technology Services

Health Technology

Health Technology

Health Technology

Health Technology

Pbm Capital Investments LLC

Technology Services

Health Technology

Commercial Services

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Paul Manning
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU